Swiss Healthtech Stock News

Board overhaul puts Lonza Group (SWX:LONN) governance in focus Lonza Group (SWX:LONN) has set out a broad board refresh, nominating tech-focused leader Sami Atiya and proposing Claudia Süssmuth-Dyckerhoff as Vice-Chair while several long-serving directors prepare to step down. See our latest analysis for Lonza Group. The board refresh headlines come at a time when Lonza Group’s 1-day share price return of 1.19% and 7-day share price return of 2.21% sit against a 1-year total shareholder...

Berner Kantonalbank (SWX:BEKN) has announced an annual dividend of CHF 10.80 per share, with the payout scheduled for May 19, 2026, following the May 15 ex-date and May 18 record date. See our latest analysis for Berner Kantonalbank. The dividend announcement comes after a period of firm momentum, with a 90 day share price return of 25.7% and a 1 year total shareholder return of 43.7%, suggesting investors have recently been more positive on Berner Kantonalbank at the current CHF337.50 share...

Holcim recently launched its Women in Sustainable Construction (WISC) initiative in the UAE, aiming to advance women across technical, operational, sustainability, and leadership roles to support the country’s shift toward a resilient, low-carbon economy. This program not only aligns Holcim with sustainability priorities but also strengthens its governance profile by embedding diversity, upskilling, and mentorship into its construction value chain. Next, we’ll explore how this push to...

ABB (SWX:ABBN) is back in focus after reporting strong Q4 results, growing orders, and outlining a CHF2.0b share buyback, alongside new contract wins in power and data centre electrification. See our latest analysis for ABB. ABB’s recent Q4 update, the CHF2.0b share buyback and new electrification contracts have arrived alongside a 30 day share price return of 13.6% and a 1 year total shareholder return of 37.6%. Together these developments point to strengthening momentum rather than a short...

CEO transition and what it means for SIG Group shareholders SIG Group (SWX:SIGN) has confirmed that Mikko Keto will take over as Chief Executive Officer on 1 March 2026. This leadership change can influence how investors think about the carton packaging specialist. See our latest analysis for SIG Group. At a share price of CHF12.54, SIG Group has seen strong short term momentum with a 90 day share price return of 47.18%. However, the 1 year total shareholder return of 36.55% decline and 3...

Idorsia (SWX:IDIA) is back on investors’ radar after securing regulator alignment in the US and Europe on a streamlined Phase 3 registration program for its Fabry disease candidate, lucerastat. See our latest analysis for Idorsia. The latest lucerastat update lands after a sharp swing in sentiment, with Idorsia’s 1 year total shareholder return very large at about 5.3x. However, the year to date share price return is slightly negative and longer term total shareholder returns over 3 and 5...

Mobimo Holding (SWX:MOBN) is back in focus after reporting full year 2025 results, with higher revaluation gains, condominium sales and rental income, along with the EMWE acquisition and an unchanged dividend proposal drawing investor attention. See our latest analysis for Mobimo Holding. The recent earnings release and EMWE acquisition come after a steady recovery in sentiment, with a 10.68% 90 day share price return and a 27.04% 1 year total shareholder return suggesting that momentum has...

Roche Holding (SWX:ROG) reported that its Phase III MAJESTY study in primary membranous nephropathy met its primary endpoint with Gazyva/Gazyvaro. The result positions Gazyva/Gazyvaro as a potential first approved treatment for this rare kidney condition. The outcome may support future regulatory submissions and broaden the medicine's approved indications. For you as an investor, this sits at the heart of what Roche does: prescription medicines targeting areas with significant unmet medical...

With a median price-to-earnings (or "P/E") ratio of close to 21x in Switzerland, you could be forgiven for feeling...

Key Insights Significant insider control over Ypsomed Holding implies vested interests in company growth H. C. Michel...

Accelleron Industries has announced a major reshaping of its Board of Directors, proposing Monika Krüsi as Chairwoman and adding Mieke Van de Capelle, while two current directors step down early as part of an accelerated succession plan ahead of the 28 April 2026 AGM. This governance renewal could recalibrate how the company sets priorities in areas such as nomination, compensation, and sustainability oversight, potentially influencing its long-term direction. We’ll now examine how this...

SGS earnings event and why it matters for shareholders SGS (SWX:SGSN) recently reported full year 2025 results, with sales of CHF 6,945 million and net income of CHF 668 million. Earnings per share from continuing operations were reported at CHF 3.48 on a basic basis. See our latest analysis for SGS. The share price reacted positively to the 2025 earnings announcement, with a 1 day share price return of 2.28%. The 90 day share price return of 3.81% and 3 year total shareholder return of...

Why the Vanrafia trial is moving Novartis shares Novartis (SWX:NOVN) is back in focus after final Phase III ALIGN data showed its drug Vanrafia slowed kidney function decline in adults with IgA nephropathy, reinforcing earlier approvals and helping spark fresh investor interest. See our latest analysis for Novartis. The Vanrafia update lands on top of a strong run for Novartis, with a 30 day share price return of 8.25% and a 90 day share price return of 18.30%. This has contributed to a 1...

Recent performance and context for UBS Group shares UBS Group (SWX:UBSG) has drawn investor attention after a monthly return of about a 16% decline and a 3‑month gain of roughly 4%, set against a backdrop of mixed shorter-term price moves. See our latest analysis for UBS Group. At a share price of CHF32.10, UBS Group’s recent 1 month share price return of a 16% decline and 7 day share price return of a 5% decline contrast with a 1 year total shareholder return of 9.8% and 5 year total...

Glarner Kantonalbank's ( VTX:GLKBN ) investors are due to receive a payment of CHF1.00 per share on 30th of April. This...

It's been a good week for Swisscom AG ( VTX:SCMN ) shareholders, because the company has just released its latest...

The board of Dätwyler Holding AG ( VTX:DAE ) has announced that it will pay a dividend of CHF3.20 per share on the 23rd...

There wouldn't be many who think Sonova Holding AG's ( VTX:SOON ) price-to-earnings (or "P/E") ratio of 22.7x is worth...

If you're looking for a multi-bagger, there's a few things to keep an eye out for. Firstly, we'll want to see a proven...

Why Holcim’s WISC initiative is catching investor attention Holcim (SWX:HOLN) has launched its Women in Sustainable Construction initiative, focusing on upskilling, industry engagement, and mentorship in the UAE. Investors are assessing what this could mean for the company’s long term positioning. See our latest analysis for Holcim. Holcim’s WISC launch comes after a softer patch in the share price, with a 7 day share price return of an 8.84% decline and a year to date share price return of a...

Comet Holding AG recently reported FY 2024 revenue growth of 12.05% and very large net income growth of 128.22%, reflecting strong demand for its X-ray and RF power solutions in semiconductor and inspection markets. This performance, combined with anticipation ahead of the 6 March 2026 earnings release and AI-driven semiconductor investment trends, is sharpening attention on how effectively Comet converts sector demand into earnings quality and cash generation. We’ll now examine how this...

Zuger Kantonalbank (SWX:ZUGER) has drawn fresh attention after launching the fully digital Vaudoise InvestPlus pension solution with Vaudoise, alongside reporting full year 2025 earnings and announcing an annual dividend of CHF 230 per share. See our latest analysis for Zuger Kantonalbank. The recent Vaudoise InvestPlus launch, together with full year 2025 results and a higher dividend, has coincided with firming momentum. This includes a 30 day share price return of 8.35% and a 1 year total...

Novartis (SWX:NOVN) reported positive final Phase III ALIGN results for Vanrafia in IgA nephropathy, indicating meaningful benefits in kidney function. The company also signed a long term supply agreement with Niowave for Actinium 225 to support its radioligand therapy portfolio. For investors watching SWX:NOVN, these updates come against a backdrop of solid recent share performance. The stock closed at CHF125.14 and is up 4.3% over the past week, 7.8% over the past month, 15.3% year to...

Key Insights Burckhardt Compression Holding's significant retail investors ownership suggests that the key decisions...